NCT06218862View on ClinicalTrials.gov

Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19

CompletedOBSERVATIONAL
Enrollment

387

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
ARDS Due to Disease Caused by SARS Co-V-2
Interventions
DRUG

Sivelestat sodium

Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.

DRUG

Control

Not use Sivelestat sodium

Trial Locations (1)

130021

Yuting Li, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER